Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression

Advances in Immunology

Volumn 117, Issue , 2013, Pages 1-38

  Ntziachristos, Panagiotis ^a,b   Mullenders, Jasper ^a,b   Trimarchi, Thomas ^a,b   Aifantis, Iannis ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromatin; DNA methylation; Drugs; Epigenetic modulators; Epigenetics; Hematopoietic malignancies; Inhibitors; Leukemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARGININE METHYLTRANSFERASE; AZACITIDINE; BELINOSTAT; CURCUMIN; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; IMATINIB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LYSINE DEMETHYLASE; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; PANOBINOSTAT; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN ARGININE METHYLTRANSFERASE; RETINOIC ACID; ROMIDEPSIN; RUXOLITINIB; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID LEUKEMIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; UNSPECIFIED SIDE EFFECT;

EID: 84876725109     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410524-9.00001-3     Document Type: Chapter

References (182)

1. Abdel-Wahab O., Adli M., Lafave L.M., Gao J., Hricik T., Shih A.H., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
2. Abdel-Wahab O., Manshouri T., Patel J., Harris K., Yao J., Hedvat C., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Research 2010, 70:447-452.
3. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
4. Aggarwal P., Vaites L.P., Kim J.K., Mellert H., Gurung B., Nakagawa H., et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 2010, 18:329-340.
5. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nature Reviews. Immunology 2008, 8:380-390.
6. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. The Journal of Biological Chemistry 2004, 279:33716-33726.
7. Bartram C.R., de Klein A., Hagemeijer A., van Agthoven T., Geurts van Kessel A., Bootsma D., et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983, 306:277-280.
8. Belkina A.C., Denis G.V. BET domain co-regulators in obesity, inflammation and cancer. Nature Reviews. Cancer 2012, 12:465-477.
9. Berman B.P., Weisenberger D.J., Aman J.F., Hinoue T., Ramjan Z., Liu Y., et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nature Genetics 2012, 44:40-46.
10. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
11. Bernt K.M., Armstrong S.A. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology/the Education Program of the American Society of Hematology 2011, 2011:354-360.
12. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
13. Bonasio R., Tu S., Reinberg D. Molecular signals of epigenetic states. Science 2010, 330:612-616.
14. Booth M.J., Branco M.R., Ficz G., Oxley D., Krueger F., Reik W., et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012, 336:934-937.
15. Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nature Genetics 1996, 14:33-41.
16. Bracken A.P., Helin K. Polycomb group proteins: Navigators of lineage pathways led astray in cancer. Nature Reviews. Cancer 2009, 9:773-784.
17. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
18. Challen G.A., Sun D., Jeong M., Luo M., Jelinek J., Berg J.S., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics 2012, 44:23-31.
19. Champagne N., Bertos N.R., Pelletier N., Wang A.H., Vezmar M., Yang Y., et al. Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. The Journal of Biological Chemistry 1999, 274:28528-28536.
20. Chen H., Gu X., Su I.H., Bottino R., Contreras J.L., Tarakhovsky A., et al. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes & Development 2009, 23:975-985.
21. Chen S., Ma J., Wu F., Xiong L.J., Ma H., Xu W., et al. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes & Development 2012, 26:1364-1375.
22. Chessells J.M., Veys P., Kempski H., Henley P., Leiper A., Webb D., et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. British Journal of Haematology 2003, 123:396-405.
23. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-Miswritten, misinterpreted and mis-erased in human cancers. Nature Reviews. Cancer 2010, 10:457-469.
24. Chiarle R., Zhang Y., Frock R.L., Lewis S.M., Molinie B., Ho Y.J., et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 2011, 147:107-119.
25. Cimmino L., Abdel-Wahab O., Levine R.L., Aifantis I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011, 9:193-204.
26. Copeland A., Buglio D., Younes A. Histone deacetylase inhibitors in lymphoma. Current Opinion in Oncology 2010, 22:431-436.
27. Couronne L., Bastard C., Bernard O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. The New England Journal of Medicine 2012, 366:95-96.
28. Cramer P., Hallek M. Hematological cancer in 2011: New therapeutic targets and treatment strategies. Nature Reviews. Clinical Oncology 2012, 9:72-74.
29. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
30. Daver N., Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology 2012, 17(Suppl. 1):S59-S62.
31. Dawson M.A., Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell 2012, 150:12-27.
32. Dawson M.A., Kouzarides T., Huntly B.J. Targeting epigenetic readers in cancer. The New England Journal of Medicine 2012, 367:647-657.
33. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
34. de Jonge H.J., Huls G., de Bont E.S. Gene expression profiling in acute myeloid leukaemia. The Netherlands Journal of Medicine 2011, 69:167-176.
35. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
36. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., et al. Mutation in TET2 in myeloid cancers. The New England Journal of Medicine 2009, 360:2289-2301.
37. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
38. Dou Y., Milne T.A., Ruthenburg A.J., Lee S., Lee J.W., Verdine G.L., et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nature Structural and Molecular Biology 2006, 13:713-719.
39. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
40. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine 2006, 355:2408-2417.
41. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
42. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics 2010, 42:722-726.
43. Ernst P., Fisher J.K., Avery W., Wade S., Foy D., Korsmeyer S.J. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Developmental Cell 2004, 6:437-443.
44. Ernst J., Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nature Biotechnology 2010, 28:817-825.
45. Ernst J., Kheradpour P., Mikkelsen T.S., Shoresh N., Ward L.D., Epstein C.B., et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011, 473:43-49.
46. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews. Genetics 2007, 8:286-298.
47. Esteller M. Epigenetics in cancer. The New England Journal of Medicine 2008, 358:1148-1159.
48. Feinberg A.P. An epigenetic approach to cancer etiology. Cancer Journal 2007, 13:70-74.
49. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
50. Filion G.J., van Bemmel J.G., Braunschweig U., Talhout W., Kind J., Ward L.D., et al. Systematic protein location mapping reveals five principal chromatin types in Drosophila cells. Cell 2010, 143:212-224.
51. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
52. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
53. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 2005, 37:391-400.
54. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
55. Gilliland D.G. Hematologic malignancies. Current Opinion in Hematology 2001, 8:189-191.
56. Gore S.D. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematology/The Education Program of the American Society of Hematology 2011, 2011:550-555.
57. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
58. Green A., Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. The New England Journal of Medicine 2010, 362:369-370.
59. Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nature Chemical Biology 2005, 1:143-145.
60. Gu Y., Nakamura T., Alder H., Prasad R., Canaani O., Cimino G., et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992, 71:701-708.
61. Guenther M.G., Levine S.S., Boyer L.A., Jaenisch R., Young R.A. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130:77-88.
62. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
63. Gupta R.A., Shah N., Wang K.C., Kim J., Horlings H.M., Wong D.J., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
64. Hakim O., Resch W., Yamane A., Klein I., Kieffer-Kwon K.R., Jankovic M., et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 2012, 484:69-74.
65. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
66. He J., Nguyen A.T., Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 2011, 117:3869-3880.
67. Hellman A., Chess A. Gene body-specific methylation on the active X chromosome. Science 2007, 315:1141-1143.
68. Heltweg B., Gatbonton T., Schuler A.D., Posakony J., Li H., Goehle S., et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Research 2006, 66:4368-4377.
69. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 2003, 349:2042-2054.
70. Ho P.A., Kutny M.A., Alonzo T.A., Gerbing R.B., Joaquin J., Raimondi S.C., et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatric Blood & Cancer 2011, 57:204-209.
71. Holm T.M., Jackson-Grusby L., Brambrink T., Yamada Y., Rideout W.M., Jaenisch R. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005, 8:275-285.
72. Holtz M.S., Forman S.J., Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2005, 19:1034-1041.
73. Hon G.C., Hawkins R.D., Ren B. Predictive chromatin signatures in the mammalian genome. Human Molecular Genetics 2009, 18:R195-R201.
74. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449:105-108.
75. Isham C.R., Tibodeau J.D., Jin W., Xu R., Timm M.M., Bible K.C. Chaetocin: A promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007, 109:2579-2588.
76. Issaeva I., Zonis Y., Rozovskaia T., Orlovsky K., Croce C.M., Nakamura T., et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Molecular and Cellular Biology 2007, 27:1889-1903.
77. Iwase S., Lan F., Bayliss P., de la Torre-Ubieta L., Huarte M., Qi H.H., et al. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 2007, 128:1077-1088.
78. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
79. Jiang H., Shukla A., Wang X., Chen W.Y., Bernstein B.E., Roeder R.G. Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Cell 2011, 144:513-525.
80. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics 2002, 3:415-428.
81. Kaelin W.G. Cancer and altered metabolism: Potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harbor Symposia on Quantitative Biology 2011, 76:335-345.
82. Klein I.A., Resch W., Jankovic M., Oliveira T., Yamane A., Nakahashi H., et al. Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell 2011, 147:95-106.
83. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
84. Kojima K., Kaneda K., Yoshida C., Dansako H., Fujii N., Yano T., et al. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13). British Journal of Haematology 2003, 120:271-273.
85. Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nature Reviews. Molecular Cell Biology 2012, 13:297-311.
86. Kosmider O., Gelsi-Boyer V., Slama L., Dreyfus F., Beyne-Rauzy O., Quesnel B., et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2010, 24:1094-1096.
87. Kruidenier L., Chung C.W., Cheng Z., Liddle J., Che K., Joberty G., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408.
88. Laird P.W., Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annual Review of Genetics 1996, 30:441-464.
89. Lee M.G., Villa R., Trojer P., Norman J., Yan K.P., Reinberg D., et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 2007, 318:447-450.
90. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine 2010, 363:2424-2433.
91. Li Z., Cai X., Cai C.L., Wang J., Zhang W., Petersen B.E., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
92. Li G., Ruan X., Auerbach R.K., Sandhu K.S., Zheng M., Wang P., et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 2012, 148:84-98.
93. Lieberman-Aiden E., van Berkum N.L., Williams L., Imakaev M., Ragoczy T., Telling A., et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009, 326:289-293.
94. Liu F., Zhao X., Perna F., Wang L., Koppikar P., Abdel-Wahab O., et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011, 19:283-294.
95. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2003, 17:637-641.
96. Lu C., Thompson C.B. Metabolic regulation of epigenetics. Cell Metabolism 2012, 16:9-17.
97. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
98. Lubitz S., Glaser S., Schaft J., Stewart A.F., Anastassiadis K. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Molecular Biology of the Cell 2007, 18:2356-2366.
99. Mar B.G., Bullinger L., Basu E., Schlis K., Silverman L.B., Dohner K., et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2012, 26:1881-1883.
100. Marcucci G., Metzeler K.H., Schwind S., Becker H., Maharry K., Mrozek K., et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:742-750.
101. Margueron R., Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nature Reviews. Genetics 2010, 11:285-296.
102. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
103. Masetti R., Serravalle S., Biagi C., Pession A. The role of HDACs inhibitors in childhood and adolescence acute leukemias. Journal of Biomedicine and Biotechnology 2011, 2011:148046.
104. McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y., et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2989-2994.
105. Meissner A., Mikkelsen T.S., Gu H., Wernig M., Hanna J., Sivachenko A., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454:766-770.
106. Metzeler K.H., Walker A., Geyer S., Garzon R., Klisovic R.B., Bloomfield C.D., et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2012, 26:1106-1107.
107. Miller S.A., Mohn S.E., Weinmann A.S. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Molecular Cell 2010, 40:594-605.
108. Mohan M., Lin C., Guest E., Shilatifard A. Licensed to elongate: A molecular mechanism for MLL-based leukaemogenesis. Nature Reviews. Cancer 2010, 10:721-728.
109. Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
110. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics 2010, 42:181-185.
111. Mullighan C.G., Zhang J., Kasper L.H., Lerach S., Payne-Turner D., Phillips L.A., et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011, 471:235-239.
112. Neff T., Sinha A.U., Kluk M.J., Zhu N., Khattab M.H., Stein L., et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:5028-5033.
113. Nishigaki M., Aoyagi K., Danjoh I., Fukaya M., Yanagihara K., Sakamoto H., et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Research 2005, 65:2115-2124.
114. Ntziachristos P., Tsirigos A., Van Vlierberghe P., Nedjic J., Trimarchi T., Flaherty M.S., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nature Medicine 2012, 18:298-301.
115. Oguro H., Yuan J., Tanaka S., Miyagi S., Mochizuki-Kashio M., Ichikawa H., et al. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. The Journal of Experimental Medicine 2012, 209:445-454.
116. Oshimo Y., Nakayama H., Ito R., Kitadai Y., Yoshida K., Chayama K., et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. International Journal of Oncology 2003, 23:1663-1670.
117. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
118. Parsons D.W., Li M., Zhang X., Jones S., Leary R.J., Lin J.C., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
119. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
120. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine 2012, 366:1079-1089.
121. Ptashne M. On the use of the word 'epigenetic'. Current Biology 2007, 17:R233-R236.
122. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. The New England Journal of Medicine 2006, 354:166-178.
123. Quesada V., Conde L., Villamor N., Ordonez G.R., Jares P., Bassaganyas L., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics 2012, 44:47-52.
124. Quivoron C., Couronne L., Della Valle V., Lopez C.K., Plo I., Wagner-Ballon O., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
125. Ram O., Goren A., Amit I., Shoresh N., Yosef N., Ernst J., et al. Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell 2011, 147:1628-1639.
126. Ribeiro A.F., Pratcorona M., Erpelinck-Verschueren C., Rockova V., Sanders M., Abbas S., et al. Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia. Blood 2012, 119:5824-5831.
127. Rivera G.K., Zhou Y., Hancock M.L., Gajjar A., Rubnitz J., Ribeiro R.C., et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005, 103:368-376.
128. Roix J.J., McQueen P.G., Munson P.J., Parada L.A., Misteli T. Spatial proximity of translocation-prone gene loci in human lymphomas. Nature Genetics 2003, 34:287-291.
129. Sauvageau M., Sauvageau G. Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299-313.
130. Sawarkar R., Paro R. Interpretation of developmental signaling at chromatin: The Polycomb perspective. Developmental Cell 2010, 19:651-661.
131. Schenk T., Chen W.C., Gollner S., Howell L., Jin L., Hebestreit K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine 2012, 18:605-611.
132. Shehzad A., Wahid F., Lee Y.S. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Archiv der Pharmazie 2010, 343:489-499.
133. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
134. Shi J., Wang E., Zuber J., Rappaport A., Taylor M., Johns C., et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene 2012, 32:930-938.
135. Shih A.H., Abdel-Wahab O., Patel J.P., Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nature Reviews. Cancer 2012, 12:599-612.
136. Simon C., Chagraoui J., Krosl J., Gendron P., Wilhelm B., Lemieux S., et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes & Development 2012, 26:651-656.
137. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: Knowns and unknowns. Nature Reviews. Molecular Cell Biology 2009, 10:697-708.
138. Smith E., Lin C., Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes & Development 2011, 25:661-672.
139. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:20980-20985.
140. Straussman R., Nejman D., Roberts D., Steinfeld I., Blum B., Benvenisty N., et al. Developmental programming of CpG island methylation profiles in the human genome. Nature Structural and Molecular Biology 2009, 16:564-571.
141. Sun Y., Jiang X., Chen S., Price B.D. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Letters 2006, 580:4353-4356.
142. Tadokoro Y., Ema H., Okano M., Li E., Nakauchi H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. The Journal of Experimental Medicine 2007, 204:715-722.
143. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
144. Tan J., Jones M., Koseki H., Nakayama M., Muntean A.G., Maillard I., et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011, 20:563-575.
145. Tan M., Luo H., Lee S., Jin F., Yang J.S., Montellier E., et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1016-1028.
146. Tefferi A., Pardanani A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2009, 23:905-911.
147. Teperino R., Schoonjans K., Auwerx J. Histone methyl transferases and demethylases; can they link metabolism and transcription?. Cell Metabolism 2010, 12:321-327.
148. Thol F., Winschel C., Ludeking A., Yun H., Friesen I., Damm F., et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 2011, 96:1870-1873.
149. Tkachuk D.C., Kohler S., Cleary M.L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992, 71:691-700.
150. Tsai M.C., Manor O., Wan Y., Mosammaparast N., Wang J.K., Lan F., et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693.
151. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
152. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
153. Uribesalgo I., Di Croce L. Dynamics of epigenetic modifications in leukemia. Briefings in Functional Genomics 2011, 10:18-29.
154. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics 2009, 41:521-523.
155. Van Neste L., Herman J.G., Otto G., Bigley J.W., Epstein J.I., Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. The Prostate 2012, 72:1248-1261.
156. Velichutina I., Shaknovich R., Geng H., Johnson N.A., Gascoyne R.D., Melnick A.M., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010, 116:5247-5255.
157. Viguie F., Aboura A., Bouscary D., Ramond S., Delmer A., Tachdjian G., et al. Common 4q24 deletion in four cases of hematopoietic malignancy: Early stem cell involvement?. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2005, 19:1411-1415.
158. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
159. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2011, 25:1153-1158.
160. Wang J., Hevi S., Kurash J.K., Lei H., Gay F., Bajko J., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nature Genetics 2009, 41:125-129.
161. Wang P., Lin C., Smith E.R., Guo H., Sanderson B.W., Wu M., et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Molecular and Cellular Biology 2009, 29:6074-6085.
162. Wang G.G., Song J., Wang Z., Dormann H.L., Casadio F., Li H., et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009, 459:847-851.
163. Wang K.C., Yang Y.W., Liu B., Sanyal A., Corces-Zimmerman R., Chen Y., et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011, 472:120-124.
164. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
165. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
166. Weber M., Hellmann I., Stadler M.B., Ramos L., Paabo S., Rebhan M., et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature Genetics 2007, 39:457-466.
167. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nature Reviews. Cancer 2011, 11:481-492.
168. Wolf J.L., Siegel D., Goldschmidt H., Hazell K., Bourquelot P.M., Bengoudifa B.R., et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia & Lymphoma 2012, 53:1820-1823.
169. Wysocka J., Allis C.D., Coonrod S. Histone arginine methylation and its dynamic regulation. Frontiers in Bioscience 2006, 11:344-355.
170. Xie Q., Bai Y., Wu J., Sun Y., Wang Y., Zhang Y., et al. Methylation-mediated regulation of E2F1 in DNA damage-induced cell death. Journal of Receptor and Signal Transduction Research 2011, 31:139-146.
171. Yamane K., Toumazou C., Tsukada Y., Erdjument-Bromage H., Tempst P., Wong J., et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006, 125:483-495.
172. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 2009, 360:765-773.
173. Yan X.J., Xu J., Gu Z.H., Pan C.M., Lu G., Shen Y., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics 2011, 43:309-315.
174. Yang X.J., Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 2007, 26:5408-5419.
175. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
176. Yoshimatsu M., Toyokawa G., Hayami S., Unoki M., Tsunoda T., Field H.I., et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. International Journal of Cancer 2011, 128:562-573.
177. Yu M., Hon G.C., Szulwach K.E., Song C.X., Zhang L., Kim A., et al. Base-resolution analysis of 5-hydroxymethylcytosine in the Mammalian genome. Cell 2012, 149:1368-1380.
178. Zhang S.J., Abdel-Wahab O. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Current Hematologic Malignancy Reports 2012, 7:34-42.
179. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
180. Zhang Y., McCord R.P., Ho Y.J., Lajoie B.R., Hildebrand D.G., Simon A.C., et al. Spatial organization of the mouse genome and its role in recurrent chromosomal translocations. Cell 2012, 148:908-921.
181. Zhou V.W., Goren A., Bernstein B.E. Charting histone modifications and the functional organization of mammalian genomes. Nature Reviews. Genetics 2011, 12:7-18.
182. Zilberman D., Gehring M., Tran R.K., Ballinger T., Henikoff S. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nature Genetics 2007, 39:61-69.